Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus

Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus (I-Seizure)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05830864

Acronym

I-Seizure

Enrollment

Registered

2023-04-26

Start date

2024-06-30

Completion date

2025-09-22

Last updated

2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Status Epilepticus

Keywords

Isoflurane

Brief summary

Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.

Detailed description

Investigators will collect in 4 ICUs the data from consecutive patients hospitalized between january 2016 and january 2023. Included patient were those treated by Isoflurane for refractory status epilepticus.

Interventions

DRUGIsoflurane

no other intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years, hospitalized in ICU between 2016-01-01 and 2023-01-01, suffering refractory status epilepticus treated by inhaled Isoflurane as third anticonvulsive therapy

Exclusion criteria

* post-anoxic refractory status epilepticus after cardiac arrest, withdrawal of consent for medical data use

Design outcomes

Primary

Measure	Time frame	Description
rate of crisis control	3 months	rate of patients with crisis control or complete awakening

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026